More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$365732893
EPS
-0.78
P/E ratio
--
Price to sales
--
Dividend yield
--
Beta
2.015495
Previous close
$4.19
Today's open
$4.12
Day's range
$3.62 - $4.20
52 week range
$1.31 - $7.80
show more
CEO
James McArthur
Employees
57
Headquarters
Boston, MA
Exchange
Nasdaq Global Select
Shares outstanding
94261055
Issue type
Common Stock
Healthcare
Biotechnology & Life Sciences
PepGen: Upgrade To 'Buy' On PGN-EDODM1 Splicing Data Comeback And 2027 Milestones
PepGen is upgraded from "Hold" to "Buy" after strong 10 mg/kg phase 2 data for PGN-EDODM1 in DM1, showing 46.5% mean splicing correction. PEPG's positive data eliminates prior outlier concerns and supports a path toward an end-of-phase 2 FDA meeting in 2H 2027, with phase 3 initiation as a potential next step. Advancement to the 12.5 mg/kg cohort and upcoming FREEDOM-OLE study readouts in early 2027 provide additional catalysts and proof-of-concept opportunities.
Seeking Alpha • Nov 12, 2026

PepGen Announces Pricing of $125 Million Public Offering
BOSTON--(BUSINESS WIRE)--PepGen Announces Pricing of $125.0 Million Public Offering.
Business Wire • Nov 12, 2026

PepGen: Stock Soars On DM1 Data, But Caution Warranted On Small Sample Sizes
PepGen Inc. surged over 100% on positive Phase 2 FREEDOM2-DM1 top-line results for PGN-EDODM1 in myotonic dystrophy type 1 (DM1). PGN-EDODM1 achieved a mean 46.5% splicing correction and notable functional improvements, with a favorable safety profile at 10 mg/kg over four doses. Despite promising data, the U.S. clinical hold persists, and the small sample size (six treated patients) warrants caution pending further results.
Seeking Alpha • Nov 11, 2026

PepGen Reports Third Quarter 2026 Financial Results and Recent Corporate Highlights
BOSTON--(BUSINESS WIRE)---- $PEPG #DM1--PepGen Reports Third Quarter 2026 Financial Results and Recent Corporate Highlights.
Business Wire • Nov 10, 2026

PepGen Stock Doubles in One Session - Here's Why
PepGen Inc. (NASDAQ:PEPG) stock surged on Tuesday with a strong session Volume of 31.855 million, compared to an average volume of 983.011 thousand, according to Benzinga Pro data.
Benzinga • Nov 10, 2026

PepGen Inc. (PEPG) Discusses FREEDOM2 Lowest Dose Cohort Safety, Splicing and vHOT Results Transcript
PepGen Inc. ( PEPG ) Discusses FREEDOM2 Lowest Dose Cohort Safety, Splicing and vHOT Results November 10, 2026 8:00 AM EST Company Participants James McArthur - President, CEO, Treasurer, Secretary & Director Paul Streck - Executive VP and Head of Research & Development Conference Call Participants Laurence Watts Konstantinos Biliouris - Oppenheimer & Co. Inc., Research Division Joseph Schwartz - Leerink Partners LLC, Research Division Paul Matteis - Stifel, Nicolaus & Company, Incorporated, Research Division Laura Chico - Wedbush Securities Inc., Research Division Debjit Chattopadhyay - Guggenheim Securities, LLC, Research Division Ananda Ghosh - H.C. Wainwright & Co, LLC, Research Division Presentation Operator Welcome to the PepGen conference call to discuss top line results from lowest dose MAD cohort in the Phase II FREEDOM2 study, demonstrating promising safety, splicing and vHOT data.
Seeking Alpha • Nov 10, 2026

PepGen Announces Positive Phase 2 FREEDOM2-DM1 10 mg/kg Results Demonstrating Highest Reported Splicing Correction and Improvements Across Multiple Functional Measures
BOSTON--(BUSINESS WIRE)---- $PEPG #DM1--PepGen Announces Positive Phase 2 FREEDOM2-DM1 10 mg/kg Results.
Business Wire • Nov 10, 2026

PepGen Announces Proposed $125.0 Million Public Offering of Common Stock
BOSTON--(BUSINESS WIRE)--PepGen Announces Proposed $125.0 Million Public Offering of Common Stock.
Business Wire • Nov 10, 2026

PepGen Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
BOSTON--(BUSINESS WIRE)---- $PEPG #DM1--PepGen Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights.
Business Wire • Aug 6, 2026

PepGen to Advance PGN-EDODM1 Into Highest Dose Cohort in Phase 2 FREEDOM2-DM1 Study Following DSMB Review
BOSTON--(BUSINESS WIRE)---- $PEPG #DM1--PepGen to Advance PGN-EDODM1 into Highest Dose Cohort in Phase 2 FREEDOM2-DM1 Study Following DSMB Review.
Business Wire • Aug 6, 2026

¹ Disclosures

Open an M1 investment account to buy and sell PepGen Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.